The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
Author: Alok Tayi
-
-
5 insights from JPM 2025
Based on JPM 2025, it’s safe to say that the biotech industry is experiencing a broad resurgence, with subtle yet significant disruption beneath the surface.
-
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
-
Biotech Limited Partners: learnings from investing in biotech venture capital funds
Limited Partners (LPs) are at the heart of the biotech funding ecosystem—these crucial players ignite the funding flywheel that drives biotech innovation.
-
Enabling every cure for community matters: Our AI-powered journey
Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures.
